KCT0007689已完成未知
An Open-Label, Two-Period, One Sequence, Drug-Drug Interaction Study to Investigate the Effect of Clarithromycin and Rifampicin on the Pharmacokinetic Profiles of DA-1229 in Healthy Adults
Dong-A ST0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 55(Year)（—）
- 性别
- Male
入选标准
- •1) Healthy male volunteers with age = 20 and = 55 years at screening
- •2) BMI = 18.5 and < 25.0 kg/m^2; where BMI (kg/m^2) = body weight (kg) / {height (m)}^2
- •3) Body weight = 55 kg
- •4) Fasting plasma glucose (FPG) = 70 mg/dL and < 100 mg/dL
- •5) Determined to be eligible for the study based on hematology, blood chemistry, immunology/serology, urinalysis as well as ECG which are selected and performed by the investigator with considering the properties of IPs as follows: (including non clinically significant abnormal)
- •- Hematology: WBC with differential count, RBC, hemoglobin, hematocrit, platelet, and PT (INR)/aPTT
- •- Blood chemistry: calcium, inorganic phosphate, fasting glucose, BUN, creatinine, cholesterol, total protein, albumin, total bilirubin, alkaline phosphatase, AST, ALT, gamma-GT, LDH, TG, K, Na, Cl, uric acid, and CPK
- •- Immunology/serology: HBsAg, anti-HCV Ab, and anti-HIV Ag/Ab
- •- Urinalysis: specific gravity, pH, protein, glucose, ketone, RBC, urobilinogen, bilirubin, nitrite, WBC, color, turbidity, and microscopy urine drug screening: amphetamine, barbiturates, morphine, benzodiazepines, and cocaine
- •6) A Subject whose partner is a woman of child-bearing potential should agree to use an appropriate method of birth control (e.g., condom) and not to donate sperm during the study and at least 28 days after the last IP administration; of note, the subject or his partner is sterile, the birth control method mentioned above is not required.
- •7) Consent to participate in the study voluntarily and comply with the precautions for the study by his signature after being fully informed and understanding of all aspects pertaining to the study.
排除标准
- •1) Known hypersensitivity to the investigational products or their excipients.
- •2) History of glucose intolerance or diabetes
- •3) History or presence of clinically significant hepatobiliary, renal, neurologic, psychiatric, pulmonary, endocrine, hematological, neoplastic, cardiovascular or immunologic disease
- •4) History of gastrointestinal disease (such as Crohn's disease or ulcer) or gastrointestinal surgery (except for appendectomy and herniotomy) possibly affecting drug absorption.
- •5) SBP < 90 mmHg or >150 mmHg, or DBP < 50 mmHg or > 100 mmHg when measured at sitting position after rest for at least 5 minutes.
- •6) Screening laboratory results as follows:total bilirubin >1.5 times the upper limit of normal values, AST (SGOT) or ALT (SGPT) > 1.25 times the upper limit of normal values, eGFR calculated by MDRD equation = 60 mL/min/1.73m^2 where eGFR (estimated glomerular filtration rate)(mL/min/1.73m^2) = 175 x [serum creatinin (mg/dL)]-1.154 x [age (year)]-0.203 (x 0.742, if female)
- •7) QTc (as QTcB; corrected by Bazett’s formula) > 450 msec or clinically significant abnormalities in ECG which may effect on the safety of subjects or the interpretation of study results.
- •8) History of significant drug abuse within 1 year prior to screening or a positive result in urine drug screening for drug abuse.
- •9) Administration of a drug, St. John’s wort or relevant preparation which may effect on the metabolism of the investigational products within 30 days prior to the first IP administration.
- •10) Applying or taking the following drugs other than oral contraceptives or topical agents of which significant amount is not absorbed systemically within certain period below:
- •prescription drugs within 14 days prior to the first IP administration; OTCs including herbal medicines or vitamin supplements within 7 days prior to the first IP administration; or depot formulations or other drugs for implantation except for contraceptives within 30 days prior to the first IP administration.
- •11) History of alcohol dependence within 1 year prior to screening, persistent consumption of alcohol (>210 units of alcohol per week) within 6 months prior to screening, or inability to abstain from drinking from 2 days prior to the first IP administration through the day of final blood sampling for pharmacokinetics.
- •12) Persistent consumption of caffeine-containing products (e.g., >5 cups of coffee, >1,250 mL of tea, or >1,250 mL of cola per day) or unable to abstain from taking caffeine-containing products from 2 days prior to the first study drug administration through the day of final blood sampling for harmacokinetics.
- •13) Smokers of more than 10 cigarettes/day persistently or unable to abstain from smoking from 2 days prior to the first IP administration through the day of final blood sampling for pharmacokinetics.
- •14) Intake of grapefruit-containing products within 7 days prior to the first IP administration.
- •15) Participation in any other clinical trial and administration of any investigational product within 60 days prior to the first IP administration except for biologics for which within 3 months and the duration can be extended considering the elimination half-life of the products.
- •16) Donation of a unit of whole blood within 60 days or blood components within 30 days prior to the first study drug administration.
- •17) Any other conditions which in the opinion of the investigator would have made the subject unsuitable for the study.
研究者
相似试验
已完成
Unknown
A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of JBPOS0101 on the Pharmacokinetics of Midazolam and the Interaction between Carbamazepine and JBPOS0101 in Healthy SubjectsDiseases of the nervous systemKCT0008374Bio-Pharm Solutions16
已完成
不适用
A Phase 1, Open-Label, Fixed Sequence Drug-Drug Interaction Study to Assess the Effect of Multiple Doses of Oral THB001 on the Pharmacokinetics of Oral Caffeine, Omeprazole, and Midazolam (CYP1A2, CYP2C19 and CYP3A4 probe substrates) in Healthy Volunteersallergic mediated diseasesand food allergychronic idiopathic and inducible urticariaallergic asthmachronic rhinosinusitisNL-OMON51382Third Harmonic Bio18
已完成
不适用
AN OPEN-LABEL, SINGLE SEQUENCE, CROSSOVER DRUG-DRUG INTERACTION STUDY ASSESSING THE EFFECT OF PEXIDARTINIB ON THE PHARMACOKINETICS OF CYP3A4 AND CYP2C9 SUBSTRATES IN PATIENTSCancerNL-OMON55479Daiichi Pharmaceutical3
尚未招募
1 期
An Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover BE Study of MONOVIR (Molnupiravir 200 mg Capsules) of GPO, Thailand with LAGEVRIO (Molnupiravir 200 mg Capsules) of Patheon Pharmaceuticals Inc., USA in Normal, Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20220508005The Government Pharmaceutical Organization58
进行中（未招募）
不适用
An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-infected subjects. - CAL102120EUCTR2004-000754-24-GBGlaxoSmithKline R&D UK Ltd30